



**Telix Pharmaceuticals Limited**  
ACN 616 620 369  
Suite 401, 55 Flemington Road  
North Melbourne  
Victoria, 3051  
Australia

---

## **Telix Pharmaceuticals 4<sup>th</sup> Annual General Meeting of Shareholders** **Results of Meeting**

Melbourne (Australia) – 12 May 2021. Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to advise that each of the resolutions put to the Annual General Meeting was passed.

All resolutions were determined by Poll.

The results provided in the attached document are provided in accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act.

### **About Telix Pharmaceuticals Limited**

Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit [www.telixpharma.com](http://www.telixpharma.com) and follow Telix on [Twitter](https://twitter.com/TelixPharma) (@TelixPharma) and [LinkedIn](https://www.linkedin.com/company/telix-pharmaceuticals).

### **Telix Corporate Contact**

Dr. Christian Behrenbruch  
Telix Pharmaceuticals Limited  
Managing Director and CEO  
Email: [chris.behrenbruch@telixpharma.com](mailto:chris.behrenbruch@telixpharma.com)

### **Telix Corporate Communications**

Dr. Stewart Holmstrom  
Telix Pharmaceuticals Limited  
Director of Corporate Communications  
Email: [stewart.holmstrom@telixpharma.com](mailto:stewart.holmstrom@telixpharma.com)

### **Important Information**

*This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the "U.S. Securities Act"), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the U.S. Securities Act or an exemption from the registration requirements of the U.S. Securities Act is available. None of the technologies or products described in this document have received a marketing authorisation in any jurisdiction. This announcement has been authorised for release by Dr Christian Behrenbruch, Managing Director and Chief Executive Officer.*

ANNUAL GENERAL MEETING  
Wednesday, 12 May, 2021

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

| Resolution Voted on at the meeting |                                                                                        |               | Proxy Votes (as at proxy close) |                    |                            |         | Poll (Manner in which votes were cast in person or by proxy on a poll (where applicable) on a poll at the meeting |                    |            |         |
|------------------------------------|----------------------------------------------------------------------------------------|---------------|---------------------------------|--------------------|----------------------------|---------|-------------------------------------------------------------------------------------------------------------------|--------------------|------------|---------|
| No                                 | Short Description                                                                      | Strike Y/N/NA | For                             | Against            | Discretionary (open votes) | Abstain | For                                                                                                               | Against            | Abstain ** | Result  |
| 1                                  | ADOPTION OF THE REMUNERATION REPORT                                                    | N             | 80,197,547<br>97.97%            | 612,453<br>0.75%   | 1,045,667<br>1.28%         | 432,594 | 82,249,204<br>99.26%                                                                                              | 612,453<br>0.74%   | 452,594    | Carried |
| 2                                  | RE-ELECTION OF DR ANDREAS KLUGE AS DIRECTOR                                            | NA            | 102,679,827<br>92.65%           | 7,096,688<br>6.40% | 1,045,667<br>0.94%         | 192,329 | 129,426,484<br>94.80%                                                                                             | 7,096,688<br>5.20% | 192,329    | Carried |
| 3                                  | APPROVAL OF ISSUE OF OPTIONS TO DR CHRISTIAN BEHRENBRUCH                               | NA            | 77,142,055<br>95.86%            | 2,287,948<br>2.84% | 1,045,667<br>1.30%         | 234,177 | 78,860,419<br>96.78%                                                                                              | 2,622,948<br>3.22% | 234,177    | Carried |
| 4                                  | APPROVAL OF AGGREGATE REMUNERATION FOR NON-EXECUTIVE DIRECTORS                         | NA            | 80,290,273<br>97.91%            | 670,625<br>0.82%   | 1,045,667<br>1.28%         | 281,696 | 82,341,930<br>99.19%                                                                                              | 670,625<br>0.81%   | 301,696    | Carried |
| 5                                  | APPROVAL OF ISSUE OF SHARES IN CONNECTION WITH THE PARTNERSHIP WITH CHINA GRAND PHARMA | NA            | 108,843,311<br>98.87%           | 163,714<br>0.15%   | 1,083,917<br>0.98%         | 923,569 | 135,628,218<br>99.88%                                                                                             | 163,714<br>0.12%   | 923,569    | Carried |
| 6                                  | APPROVAL OF ISSUE OF SHARES IN CONNECTION WITH ACQUISITION OF THERAPHARM GMBH          | NA            | 109,664,981<br>98.95%           | 112,498<br>0.10%   | 1,045,917<br>0.94%         | 191,115 | 136,411,888<br>99.92%                                                                                             | 112,498<br>0.08%   | 191,115    | Carried |
| 7                                  | ADOPTION OF TELIX EQUITY INCENTIVE PLAN                                                | NA            | 77,198,775<br>95.95%            | 2,210,944<br>2.75% | 1,045,917<br>1.30%         | 254,211 | 79,252,389<br>97.29%                                                                                              | 2,210,944<br>2.71% | 254,211    | Carried |

\*\* - Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item